Blog

25 Mar

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage Corp. I

March 24, 2022
Posted by Jitendra

PALO ALTO, CA. March 25, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid...

21 Mar

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

21 Mar

SEC FIlings

Current report

November 17, 2022
Posted by Jitendra

18 Mar

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

18 Mar

Press Release

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for First to Market Opportunity

March 18, 2022
Posted by Jitendra

SP-102 (SEMDEXA™), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in Radiculopathy) experienced a rapid onset of pain relief, measured by Numeric Pain Rating Scale of average daily...

17 Mar

Press Release

Scilex Holding Company, a Majority-owned Subsidiary OF Sorrento Therapeutics, Inc., to Become Publicly Traded Through a Merger With Vickers Vantage Corp. I

March 17, 2022
Posted by Jitendra

• Combined company expected to have a pro forma equity value post-money of approximately $1.64 billion, subject to potential adjustment, and with up to $140 million in expected gross proceeds before...

24 Feb

SEC FIlings